A Contemporary Pediatrics Peer Exchange panel reviews RSV risk, testing, maternal vaccination, and long-acting monoclonal antibodies, and where infants still slip through the cracks.
|Videos|November 4, 2022
RSV, influenza, and COVID-19: Gearing up for the threat of a 'triple epidemic'
Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, sits down to discuss the rising threat of a "triple epidemic" consisting of influenza, COVID-19, and RSV in children.
Advertisement
Contemporary Pediatrics® Editor-in-Chief Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, sits down to discuss the recent surge in pediatric RSV hospitalizations and the rising threat of the "triple epidemic" consisting of influenza, COVID-1, and RSV in children.
Advertisement
Related to this article
Completing the DTaP primary series was 96.2% effective against pertussis in Alaska children aged 6 months to 6 years during a record 2024 outbreak.
Diana F. Clarke, PharmD, explains how IMPAACT 2023 supported dolutegravir from birth, plus dosing tips and open questions for preterm infants.
Find out the 4 FDA decisions to watch in November 2026 for pediatric care.
Cenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.
FDA approved Lupin's generic of Firdapse for LEMS in patients 6 years and older, but a patent settlement delays US marketing until at least 2035.
CDC confirmed the first pediatric flu death of 2026-27, linked to H1N1, as early flu activity rises in 2026.
A recap of the top pediatric clinical trial results and pipeline data readouts during October 2026.
Advertisement
Advertisement